The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to ...
Results recently published from the phase 2 HIMALAYA trial reported that SAR443820 did not slow functional decline, and was associated with more adverse events and treatment discontinuations in ...
Beginning with FDA news, the administration Xenon Pharmaceuticals has submitted a new drug application (NDA) to the FDA for ...
In recognition of International Ataxia Awareness Day, observed annually on NeurologyLive® reviews 6 investigational agents ...
Neurology moves fast, and the assumptions that shape how we practice do not always keep up. Gray Areas is a NeurologyLive ...
Exploring the Link Between Football Players and ALS: Brian Lin, PhD In a recent Q&A interview, Brian Lin, PhD, research ...
In this episode, host Lindsay Ross, MD, is joined by joined by Rachel Galioto, PhD, a Cleveland Clinic neuropsychologist ...
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
Twelve observational studies (1997–2025) demonstrated a bidirectional migraine–colic association, including both maternal ...
In early September, the FDA approved zilganersen injection (Zanvastro; Ionis) for the treatment of Alexander disease in pediatric and adult patients, marking the first approved th ...
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results